Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
Citrix Systems’ $16.5 Billion Acquisition of Vista Equity Partners and Evergreen Coast Capital’s Affiliates
Goodwin Procter advised Citrix Systems on the deal. Citrix Systems announced its acquisition by affiliates of Vista Equity Partners and Evergreen Coast Capital Corporation, an affiliate of...
Royalty Pharma’s Acquisition of Royalty Interest in TRELEGY ELLIPTA
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
Royalty Pharma’s Acquisition of Theravance Respiratory Company
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
Vista and Evergreen’s $16.5 Billion Acquisition of Citrix
Kirkland & Ellis and Kinstellar advised Vista, and Gibson, Dunn & Crutcher and Debevoise & Plimpton advised Evergreen. Goodwin Procter represented Citrix in the transaction. Wilson...
Vigil Neuroscience’s $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
MorphoSys’ $1.7 Billion Acquisition of Constellation Pharmaceuticals
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...